title: [Cancer curable by chemotherapy: malignant lymphoma].
abstract: The trends in the rationale of chemotherapy for malignant lymphoma are to use combination regimen, non-cross resistant alternating regimen, and hybrid regimen. Long follow-up results of chemotherapy of lymphoma were summarized as follows: for Hodgkin's disease, MOPP regimen of 20 years from NCI in 188 patients (pts) with 84% CR rate and 54% (101 pts) relapse-free (RF) at 15 years, and MOPP-ABV hybrid regimen in 76 pts with 97% CR rate and 90% RFS rate at 7 years; for non-Hodgkin's lymphoma (NHL), results of three generations are reported: the first generations were the first generation (CHOP, BACOP, 40-50s% CR rate and 30s% long-term survivors), the second generation (Pro-MACE/MOPP, 70s% and 40-50s%) and the third generation (MACOP-B, 80s% and 60-70s%). MACOP-B regimen in 125 pts with large-cell lymphoma showed 84% CR rate and 69% RFS rate and 69% RFS rate at 6.5 years. In our studies with four regimens of VCP, AVCP, AVCP/EMLP and B-AVCR/EMVP, CR rate was 56% in 101 pts, and 26 pts are still in CR among 40 living pts. The CR rate and the RSF rate reported in Japan are generally still low for curability of NHL.
authors.affiliation: Dept. of Clinical Oncology, Japanese Foundation for Cancer Research.
authors.forename: N
authors.initials: N
authors.lastname: Horikoshi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone